Favipiravir PEP shows non-significant reduction in SARS-CoV-2 infection among household contacts in Thailand trialCan a pill protect you after a family member gets COVID?

Journal of infection and public health Published April 4, 2026 Study authors: Siripongboonsitti Taweegrit, Ungtrakul Teerapat, Tawinprai Kriangkrai, Niemsorn Krongkwan, Punjachai… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider favipiravir PEP findings preliminary; infection reduction was not statistically significant in this phase 2/3 trial.

This phase 2/3 cluster-randomized controlled trial evaluated favipiravir post-exposure prophylaxis (FPV-PEP) for preventing SARS-CoV-2 infection among household contacts in Thailand. The study included 168 close contacts from 76 index cases, comparing FPV-PEP (1600-2000 mg/day for 7 days) against usual care. The primary outcome was incidence of confirmed SARS-CoV-2 infection.

Results showed a lower incidence of infection in the FPV-PEP group (7.32%) compared to usual care (14.47%), though this difference did not reach statistical significance. Secondary outcomes suggested less frequent symptom development (fever, rhinorrhea, myalgia), a higher probability of remaining asymptomatic, and delayed symptom onset among FPV-PEP recipients, though exact numbers for these outcomes were not reported.

No participants developed severe COVID-19 or required hospitalization. The study had several limitations: it was open-label, the primary outcome difference was not statistically significant, and it was a phase 2/3 trial. Key details including follow-up duration, adverse events, and funding sources were not reported.

For clinical practice, these findings represent early evidence that requires confirmation. The observed association between FPV-PEP and reduced infection/symptoms should be interpreted cautiously given the non-significant primary outcome and open-label design.

Imagine a family member tests positive for COVID-19. You're living in the same house, worried you're next. Researchers in Thailand tested whether taking an antiviral pill called favipiravir for seven days right after that exposure could protect you.

They studied 168 people who were close household contacts of someone with confirmed COVID. Those who took the drug had a lower rate of infection (7.32%) compared to those who got usual care (14.47%). People on the drug also seemed to have fewer symptoms like fever and muscle aches, a higher chance of staying symptom-free, and a delay in when symptoms started if they did get sick.

It's important to note that the main difference in infection rates wasn't statistically significant, meaning we can't be certain it wasn't just due to chance. The study was also open-label, meaning people knew which treatment they were getting, which can sometimes influence results. No one in the study developed severe COVID or needed hospitalization. This was a phase 2/3 trial, so it's an early look at a possible use for this drug, not a final answer.

What this means for you:

An antiviral pill showed promise for preventing COVID after exposure, but more evidence is needed.

Study Details

Study typeRct

EvidenceLevel 2

PublishedApr 2026

PMID41637930

View Original Abstract ↓

BACKGROUND: Household transmission of SARS-CoV-2 remains a key driver of community spread, with secondary attack rates in Thai households reaching approximately 50 %. There is limited evidence supporting the efficacy of antiviral post-exposure prophylaxis (PEP) in this context. METHODS: The phase 2/3, open-label, (1:1) cluster-randomized controlled trial in Thailand, 168 household close contacts from 76 index cases were enrolled to receive either favipiravir-PEP (FPV-PEP) (1600-2000 mg/day for 7 days) or usual care. The efficacy of FPV-PEP was investigated in preventing SARS-CoV-2 infection after contact with index cases. RESULTS: The incidence of confirmed SARS-CoV-2 infection was lower in the FPV-PEP group than in the usual care group (7.32 % vs. 14.47 %), although the difference was not statistically significant. A trend toward fewer early positive rapid diagnostic test results on day 3 was observed in the FPV-PEP group. Symptom development was less frequent among FPV-PEP recipients, with fewer cases of fever, rhinorrhea, and myalgia. A significantly higher probability of remaining asymptomatic and delayed symptom onset was observed in the FPV-PEP group. No participants developed severe COVID-19 or required hospitalization. CONCLUSION: FPV-PEP was associated with a lower incidence of fever, rhinorrhea, and myalgia among household contacts. While a reduction in secondary transmission was observed, it did not reach statistical significance. Further large-scale studies are warranted to clarify its role in preventing household transmission.

Favipiravir PEP shows non-significant reduction in SARS-CoV-2 infection among household contacts in Thailand trialCan a pill protect you after a family member gets COVID?

Study Details

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

Clinical research that matters. Delivered to your inbox.

Favipiravir PEP shows non-significant reduction in SARS-CoV-2 infection among household contacts in Thailand trialCan a pill protect you after a family member gets COVID?

More on COVID

Study Details

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

Clinical research that matters. Delivered to your inbox.

Related in Infectious Disease

From Other Specialties